Ureteral Calculi, Hyperalgic, Not Complicated Clinical Trial
Official title:
Interest of Néfopam in the Treatment of Pain During the Intense Ureteral Calculi Uncomplicated in Adults in Emergencies Unit.
| Verified date | March 2010 |
| Source | University Hospital, Clermont-Ferrand |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | France: Ministry of Health |
| Study type | Interventional |
The administration of néfopam after initial treatment by kétoproféne, could obtain, in
patients remaining pain and classically need morphine, analgesia at least the same as
morphine alone. The use of néfopam second line after ketoprofen could reducing (or even
eliminating) the need for morphine (and its side effects), allowing a reduction in the
length of stay of patients in the emergency unit.
The main objective is to show that the addition of a néfopam initial treatment with the
kétoproféne, reduces, in patients with ureteral calculi, the percentage of patients
requiring the use of a treatment by morphine.
The secondary objective is to reduce the side effects caused by the morphine, shorten the
time to install the appropriate level of analgesia while reducing the risk of failure of the
titration morphine, reduce the time spent on titration of morphine and reduce the length of
stay patient intake in emergency unit.
| Status | Completed |
| Enrollment | 52 |
| Est. completion date | September 2009 |
| Est. primary completion date | November 2008 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 50 Years |
| Eligibility |
Inclusion Criteria: - Age between 18 to 50 years old. - Admitted to the emergency room for typical ureteral calculi with severe pain (VAS > or = 60), and microscopic hematuria in the strip without signs of urinary complications. - Preliminary Agreement patient. Exclusion Criteria: - Patient disagree. - Pregnant women (sought by the questioning). - Fever > 38 ° C. - Leucocyturie or nitriturie (dipstick). - Contraindication to ketoprofen. - Contraindication to néfopam. - Contraindication to morphine. - Contraindication linked to drug interactions as mentioned in the Summary of Product Characteristics of the Authorization for placing on the market of Acupan ®. - Treatment opioid analgesics, nonsteroidal anti-inflammatory or inflammatory or paracetamol in the previous 12 hours. - Secondary exclusion to a urinary tract infection or systemic. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| France | CHU Clermont-Ferrand | Clermont-Ferrand |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Clermont-Ferrand |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Need to use morphine as an analgesic scheme (binary yes/no) | As analgesic scheme | No | |
| Secondary | Quantity of morphine consumed after titration (mg and number of bolus) | After titration and after administration of placebo or néfopam | No | |
| Secondary | Pain (measured by the EVA) after administration of placebo or néfopam | After titration and after administration of placebo or néfopam | No | |
| Secondary | Simplified verbal Scale of Satisfaction | After titration and after administration of placebo or néfopam | No |